Roche secures CE Mark approval for its automated mass spectrometry antibiotic monitoring reagents, expanding clinical ...

Caris Life Sciences, Inc. is rated a Hold with positive EBITDA & free cash flow driven by strong MI segment performance. Read ...

In December 2025, Genentech, part of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab for adults with relapsed or refractory ...

The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.

Roche’s executives at JP Morgan 2025 spoke candidly about the company’s need to be more deliberate in its approach on how ...

US FDA approves Roche’s Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma: Basel Tuesday, December 23, 2025, 13:00 Hrs [IST] Roche announced that ...

The event, organized by Roche Diagnostics at The Avenues Mall and sponsored by the Kuwait Diabetes Society, promotes early ...

Aortic stenosis is a narrowing of the aortic valve which connects the heart to the rest of the body. It affects millions of people and can be fatal if left untreated. At present, there are no ...

Roche’s cobas BV/CV assay gains CE Mark, enabling accurate, rapid diagnosis of bacterial vaginosis and candida vaginitis.

Canaccord analyst Kyle Mikson raised the firm’s price target on Illumina (ILMN) to $130 from $112 and keeps a Hold rating on the shares. The firm ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability of Lunsumio VELO allows treatment aligned to people's clinical needs and personal preferences Approval ...

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...